- Home
- PALI
PALI
Palisade Bio Inc.
as 03-28-2025 4:00pm EST
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $23.00 | AVG Volume (30 days): | 704.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $9.65 | Next Earning Date: | 03-24-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palisade Bio Inc. News
PALI Breaking Stock News: Dive into PALI Ticker-Specific Updates for Smart Investing
GlobeNewswire
15 days ago
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
GlobeNewswire
17 days ago
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025
GlobeNewswire
25 days ago
Palisade Bio Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
a month ago
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
GlobeNewswire
a month ago
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
GlobeNewswire
2 months ago
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
GlobeNewswire
2 months ago
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
GlobeNewswire
2 months ago
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Compare PALI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PALI Palisade Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.